A5015280001- Multiple Sclerosis Research Studies
- Autoimmune and Inflammatory Disorders Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- T-cell and Retrovirus Studies
- Immune Response and Inflammation
- Ultrasound Imaging and Elastography
- Olfactory and Sensory Function Studies
- Immunotherapy and Immune Responses
- Lymphoma Diagnosis and Treatment
- Fungal Infections and Studies
- Cutaneous lymphoproliferative disorders research
- Cell Adhesion Molecules Research
- Genetic Neurodegenerative Diseases
- Sphingolipid Metabolism and Signaling
- Ultrasound and Hyperthermia Applications
- NF-κB Signaling Pathways
University of Naples Federico II
2022-2024
Federico II University Hospital
2024
Backgroundin the early stages of Multiple Sclerosis (MS), initiating high-efficacy disease-modifying therapy (HE DMTs) may represent an optimal strategy for delaying neurological damage and long-term disease progression, especially in highly active MS patients (HAMS). Natalizumab (NAT) Ocrelizumab (OCR) are recognized as HE DMTs with significant anti-inflammatory effects. This study investigates NEDA-3 achievement treatment-naïve HAMS receiving NAT or OCR over three years.Methodswe...
Abstract Background Circulating immune cells play a pathogenic role in multiple sclerosis (MS). However, the of specific lymphocyte subpopulations is not unveiled yet, especially progressive stages. We aimed to investigate changes during siponimod treatment active secondary MS (aSPMS) and their associations with clinical outcomes. Methods enrolled 46 aSPMS patients starting on at least 6 months follow-up two visits within scheduled timeframes 14 sex- age-matched healthy controls (HCs)....
Gait impairment is common in multiple sclerosis (MS), but difficult to evaluate clinical practice. In this proof-of-concept observational study, we compared walking ability recorded by Google Maps Timeline conventional measures people with MS.We used open-access record the total number of days activity, distance, time, and speed. Each variable was included a different stepwise linear regression model including all variables.We nine MS (age 43.1 ± 6.6 years; females 55.6%; disease duration...
Introduction: Although panniculitis-like T cell lymphoma (SPTCL) and hemophagocytic syndrome (HSP) have been described as complications following immunosuppressive treatments, there are no reported cases of concomitant SPTCL/HSP multiple sclerosis (MS). Materials Methods: We describe the case a patient affected by an aggressive phenotype relapsing remitting MS, characterized consecutive severe relapses with complete remission. He developed after receiving treatments in sequence. Despite...